TABLE 4.

Laboratory and Clinical Outcomes According to Study Group

	Control Group (n = 47)	Monitor Group (n = 46)	P Value
Duration of UAC use, d	5.8 (4.5–8.7)	6.6 (3.8–10.2)	.57
Laboratory data on day 7
Hemoglobin, g/L	134 ± 17.4 [44]	135.1 ± 19.3 [43]	.29
Hemoglobin change from day 1, g/L	−7.8 [42]	−7.6 [41]	.98
Laboratory data on day 14
Hemoglobin, g/L	138 ± 14.8 [42]	131.9 ± 14.4 [41]	.07
Hemoglobin change from day 1, g/L	−9.3 [42]	−10.1 [41]	.83
Plasma ferritin, μg/L	464 (299–605) [38]	489 (274–709) [37]	.78
Ferritin change from day 1, μg/L	283 (126–403) [35]	338 (67–493) [37]	.62
Mechanical ventilation other than CPAP, n (%)	44 (94)	43 (94)	.99
Postnatal corticosteroids, n (%)	17 (36)	20 (44)	.53
Intraventricular hemorrhage grade III/IV, n (%)	7 (15)	8 (17)	.78
Patent ductus arteriosus, n (%)	29 (62)	21 (46)	.15
Oxygen treatment at 36 wk, n (%)	26/47 (55)	29/46 (63)	.53
Bacteremia during study (≤14 d), n (%)	2 (4)	6 (13)	.16
Bacteremia after study (>14 d), n (%)	9 (21) [42]	7 (17) [41]	.78
Necrotizing enterocolitis (Bell's stage ≥II), n (%)	5 (11)	2 (4)	.43
Threshold retinopathy of prematurity, n (%)*	3 (15) [39]	4 (14) [35]	.70
Periventricular leukomalacia, n (%)*	2 (5)	0 (0)	.49
Survival without severe morbidity, n (%)†	21/41 (51)	15/37 (40)	.37
Age at discharge, d	102 (86–121)	91 (77–124)	.68
Weight at discharge, g	2760 (2260–3300)	2660 (2410–3109)	.84

Data are expressed as the mean ± SD, the median (interquartile range), or the number of subjects (percentage of subjects); numbers in square brackets are numbers if different from group numbers. CPAP indicates continuous positive airway pressure.

^*Treated with laser therapy or cryotherapy.

^†Without oxygen treatment at 36 weeks, threshold retinopathy of prematurity, bacteremia after 3 days of life, periventricular leukomalacia, pneumothorax, intraventricular hemorrhage (grades III or IV), or necrotizing enterocolitis (Bell's stage ≥II).¹⁹